These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 24634938)

  • 1. Somatostatin receptor 1 (SSTR1) and somatostatin receptor 5 (SSTR5)expression in hepatocellular carcinoma.
    Koc EU; Ozgur T; Yerci O; Gurel S
    Hepatogastroenterology; 2013 Oct; 60(127):1693-7. PubMed ID: 24634938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1--5 and correlation with receptor protein expression and tumor pathology.
    Kumar U; Grigorakis SI; Watt HL; Sasi R; Snell L; Watson P; Chaudhari S
    Breast Cancer Res Treat; 2005 Jul; 92(2):175-86. PubMed ID: 15986128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation of somatostatin receptor expression in human hepatocellular carcinoma tissue to serum alpha-fetoprotein concentration].
    Xie YM; Yan LN; Wei B; Guo MM; Tang CW
    Ai Zheng; 2007 Jul; 26(7):688-92. PubMed ID: 17626741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of somatostatin receptor 2 and 5 expression in operable hepatocellular carcinomas.
    Li S; Liu Y; Shen Z
    Hepatogastroenterology; 2012 Oct; 59(119):2054-8. PubMed ID: 22640914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas.
    Bläker M; Schmitz M; Gocht A; Burghardt S; Schulz M; Bröring DC; Pace A; Greten H; De Weerth A
    J Hepatol; 2004 Jul; 41(1):112-8. PubMed ID: 15246216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets.
    Kaemmerer D; Schindler R; Mußbach F; Dahmen U; Altendorf-Hofmann A; Dirsch O; Sänger J; Schulz S; Lupp A
    BMC Cancer; 2017 Dec; 17(1):896. PubMed ID: 29282035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice.
    Barbieri F; Pattarozzi A; Gatti M; Aiello C; Quintero A; Lunardi G; Bajetto A; Ferrari A; Culler MD; Florio T
    Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1078-88. PubMed ID: 19706788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization.
    Reubi JC; Schaer JC; Waser B; Mengod G
    Cancer Res; 1994 Jul; 54(13):3455-9. PubMed ID: 8012966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas.
    de Sá SV; Corrêa-Giannella ML; Machado MC; de Souza JJ; Pereira MA; Patzina RA; Siqueira SA; Machado MC; Giannella-Neto D
    Endocr Relat Cancer; 2006 Mar; 13(1):69-78. PubMed ID: 16601280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.
    Zatelli MC; Piccin D; Tagliati F; Bottoni A; Luchin A; Vignali C; Margutti A; Bondanelli M; Pansini GC; Pelizzo MR; Culler MD; Degli Uberti EC
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2218-24. PubMed ID: 16569735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis.
    Kumar U; Sasi R; Suresh S; Patel A; Thangaraju M; Metrakos P; Patel SC; Patel YC
    Diabetes; 1999 Jan; 48(1):77-85. PubMed ID: 9892225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis.
    Lequoy M; Desbois-Mouthon C; Wendum D; Gupta V; Blachon JL; Scatton O; Dumont S; Bonnemaire M; Schmidlin F; Rosmorduc O; Fartoux L
    Histopathology; 2017 Feb; 70(3):492-498. PubMed ID: 27391928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.
    Kubota A; Yamada Y; Kagimoto S; Shimatsu A; Imamura M; Tsuda K; Imura H; Seino S; Seino Y
    J Clin Invest; 1994 Mar; 93(3):1321-5. PubMed ID: 8132773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer.
    Qiu CZ; Wang C; Huang ZX; Zhu SZ; Wu YY; Qiu JL
    World J Gastroenterol; 2006 Apr; 12(13):2011-5. PubMed ID: 16610049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deficiency of somatostatin (SST) receptor type 5 (SSTR5) is associated with sexually dimorphic changes in the expression of SST and SST receptors in brain and pancreas.
    Ramírez JL; Grant M; Norman M; Wang XP; Moldovan S; de Mayo FJ; Brunicardi C; Kumar U
    Mol Cell Endocrinol; 2004 Jun; 221(1-2):105-19. PubMed ID: 15223137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming growth factor α immunoreactivity. A study in hepatocellular carcinoma and in non-neoplastic liver tissue.
    Pannain VL; Morais JR; Damasceno-Ribeiro O; Avancini-Alves V
    Ann Hepatol; 2012; 11(4):495-9. PubMed ID: 22700631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of soluble transferrin receptors study in hepatocellular carcinoma with underlying cirrhosis.
    Mehta R; Suvarna D; Mustafa CP; Sadasivan S
    Indian J Cancer; 2005; 42(4):215. PubMed ID: 16391443
    [No Abstract]   [Full Text] [Related]  

  • 18. Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors.
    Schmid HA; Lambertini C; van Vugt HH; Barzaghi-Rinaudo P; Schäfer J; Hillenbrand R; Sailer AW; Kaufmann M; Nuciforo P
    Neuroendocrinology; 2012; 95(3):232-47. PubMed ID: 22156600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance.
    Silva CB; Ongaratti BR; Trott G; Haag T; Ferreira NP; Leães CG; Pereira-Lima JF; Oliveira Mda C
    Int J Clin Exp Pathol; 2015; 8(10):13185-92. PubMed ID: 26722517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.